UK-based pharmaceutical major AstraZeneca has started global withdrawal of its Covid-19 vaccine, which was provided in India as “Covishield'” in partnership with Serum Institute.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzervria,” they said.
They added, “We will now work with regulators and partners to align on a clear path forward to conclude this chapter and make a significant contribution to the Covid-19 pandemic.”
A blood clot in the blood vessel can cause thrombosis, which can reduce blood flow. Meanwhile, Thrombocytopenia occurs during low blood platelet count in the body.
According to Indian government data, 92,479 citizens had been hospitalised due to Adverse Event Following Immunisation in the country, which meant one out of 23,000 recipients.